US Physician Paradigm Study Informs Decision-Making in Locally Advanced/Metastatic Urothelial Carcinoma

home / between-the-lines / disease-management-and-frontline-treatment-of-locally-advanced-or-metastatic-urothelial-la-muc-c

Shilpa Gupta, MD, and Vinit Makkar, MD, discuss the treatment patterns and disease management of locally advanced/metastatic urothelial carcinoma, with a focus on data from the US physician-based PARADIGM study.

Overview of Locally Advanced/Metastatic Urothelial Carcinoma

EP. 1: Overview of Locally Advanced/Metastatic Urothelial Carcinoma

Shilpa Gupta, MD;Vinit Makkar, MD
July 7th 2022

Vinit Makkar, MD, provides a brief overview of locally advanced/metastatic urothelial carcinoma (la/mUC), available first-line (1L) and first-line maintenance (1LM) treatment options, and unmet needs in the field.

Scope and Methods of the PARADIGM Study and Expert Commentary on Treatment Decision-Making

EP. 2: Scope and Methods of the PARADIGM Study and Expert Commentary on Treatment Decision-Making

Shilpa Gupta, MD;Vinit Makkar, MD
July 7th 2022

Shilpa Gupta, MD, describes the scope and methods of the PARADIGM study, which examines recent systemic anti-cancer treatment patterns in la/mUC.

Shilpa Gupta, MD, and Vinit Makkar, MD

EP. 3: Perspectives on First-Line Treatment Decision-Making for la/mUC: Results of The Targeted Literature Search and Qualitative Interviews

Shilpa Gupta, MD;Vinit Makkar, MD
July 14th 2022

Experts discuss results from the targeted literature search and qualitative interviews, which identify important factors that impact their treatment decisions for patients with locally advanced/metastatic urothelial carcinoma.

A Cross-Sectional Survey Reveals Physicians’ Treatment Patterns in First-Line and Maintenance Therapy for la/mUC

EP. 4: A Cross-Sectional Survey Reveals Physicians’ Treatment Patterns in First-Line and Maintenance Therapy for la/mUC

Shilpa Gupta, MD;Vinit Makkar, MD
July 14th 2022

Drs Gupta and Makkar discuss results from the PARADIGM cross-sectional survey, which reveals physicians’ 1L and 1LM treatment patterns in la/mUC.

Key Factors Associated with First-Line and Maintenance Therapy Prescription Frequency

EP. 5: Key Factors Associated with First-Line and Maintenance Therapy Prescription Frequency

Shilpa Gupta, MD;Vinit Makkar, MD
July 21st 2022

A look at the key factors associated with 1L and 1LM therapy prescription frequency in the PARADIGM study.

Key Takeaways from the PARADIGM Study

EP. 6: Key Takeaways from the PARADIGM Study

Shilpa Gupta, MD;Vinit Makkar, MD
July 21st 2022

Drs Gupta and Makkar conclude their discussion by highlighting key takeaways from the PARADIGM study and future directions that may address unmet needs in the field of la/mUC.

Recap: US Physician PARADIGM Study Informs Decision-Making in Locally Advanced/Metastatic Urothelial Carcinoma

EP. 7: Recap: US Physician PARADIGM Study Informs Decision-Making in Locally Advanced/Metastatic Urothelial Carcinoma

ONCOLOGY Staff
August 27th 2022

Shilpa Gupta, MD, and Vinit Makkar, MD, discuss the treatment patterns and disease management of locally advanced/metastatic urothelial carcinoma, with a focus on data from the US physician-based PARADIGM study.